Range Energy spuds their Shewashan-3 well

Range Energy Resources' {CSE: RGO}, contractor of the Khalakan PSC in the Kurdistan region of Iraq, Gas Plus Khalakan, has issued an operations update regarding the Shewashan field.

The GPK Shewashan operations update provides details regarding key events and activities that have occurred.

Range Energy Resources spuds Shewashan-3 well

2016-08-15 08:52 ET – News Release

Mr. Toufic Chahine reports

RANGE ENERGY RESOURCES INC. : SHEWASHAN OPERATIONS UPDATE

Range Energy Resources Inc.'s {CSE: RGO} contractor of the Khalakan PSC in the Kurdistan region of Iraq, Gas Plus Khalakan, has issued an operations update regarding the Shewashan field.

The GPK Shewashan operations update provides details regarding key events and activities that have occurred, as well as activities that are anticipated to occur over the near term, including:

-- Oil Production: The Shewashan-2 well continues to produce with a current
rate of circa 4,000 bopd and the production from both wells is sold into
the domestic refinery market via existing topside production facilities

and tanker trucks. GPK anticipates total field production to reach the target 10,000 bopd early next year when Shewashan-4 will come on stream.

Proceeds for oil sales from initial production in April through to end June 2016 have been invoiced and agreed with the MNR. These invoices are expected to be settled shortly and on a monthly basis going forward;

-- Shewashan-1 Sidetrack: The Shewashan-1 Sidetrack well was successfully drilled and recompleted as a horizontal producing well in the Qamchuga formation. The well is currently producing approximately 500-700 bopd and the well completion may require further stimulation to reach expected predrill production estimates based upon the original Shewashan-1 vertical well. The Shewashan-1 vertical well bore remains a future candidate for additional horizontal sidetrack wells or a recompletion of the Shewashan-1 Sidetrack horizontal sidetrack to further enhance the well's productive capacity;

-- Drilling Activity: The Shewashan-3 well has now spudded and this well will again target the productive Cretaceous formations as a vertical producer. The well is anticipated to be completed in Q4 2016 with an estimated budget of USD 16 million. The vertical Shewashan-4 well is due to be drilled later this year to accelerate Phase 1 production in the Cretaceous and test the deeper unexplored Jurassic reservoirs;

-- Khalakan PSC: GPK and the KRG Ministry of Natural Resources have agreed to adjustments that GPK believes brings the Khalakan Production Sharing Contract in line with other PSC terms in respect to the infrastructure payment arrangement and which is neutral to the contractor at current oil prices; and

-- Reserve Report: GPK intends to engage DeGolyer and MacNaughton to update its June 2015 reserve audit during Q4 2016. Based on the productivity of the Cretaceous reservoir and some new mapping since the last reserve audit, we expect a modest increase in calculated reserves.

Mr. Toufic Chahine, Chairman of Range, commented: "*Steady progress continues to be made on the Shewashan field. We are pleased to hear that GPK is actively working to settle invoiced amounts for produced oil. Production and the receipt of sales proceeds will represent a significant milestone for Range and the development of the Shewashan field. Furthermore, drilling activity continues to further delineate the Shewashan field, with the Shewashan-3 well currently drilling away, and the Shewashan-4 well to follow with targets in both the cretaceous and the lower, unexplored formations*."

The full text of the GPK Operations Update can be accessed HERE:

The Company is a 24.95% indirect shareholder of GPK through its ownership of 49.9% of the shares of New Age Alzarooni 2 Limited (“NAAZ2”). NAAZ2 owns 50% of the shares of GPK.

For further information please visit – www.rangeenergyresources.com

We seek Safe Harbor.

Kootenay partner Pan American Silver drilling at Promontorio

Kootenay Silver {TSX.V:KTN} reports that partner **Pan American Silver Corp. [TSX: PAA}** has provided an update on exploration on the Promontorio-La Negra silver prospect, contained within the Promontorio Mineral Belt, Sonora, Mexico.

Kootenay Silver {TSX.V:KTN} reports that its partner, **Pan American Silver Corp. [TSX: PAA}** has provided an update on exploration on the Promontorio-La Negra silver prospect, contained within the Promontorio Mineral Belt, Sonora, Mexico.

A 3,400-metre diamond drilling program is underway and will consist of about 18 drill holes. The program will further test the La Negra Breccia and two additional targets.

James McDonald, President and CEO of Kootenay Silver, said, "*We are very pleased with the results to date from Pan American's exploration activities on Promontorio-La Negra. The La Negra silver discovery is a premier exploration target that demonstrates excellent potential to evolve into a low-cost, open-pittable silver resource. We are excited the drill campaign on La Negra is underway and look forward to reporting results as they are received from the program*."

Promontorio – La Negra Silver Discovery

An updated measured and indicated resource at Promontorio contains an estimated 92,035,000 silver equivalent ounces with another 24,326,000 silver equivalent ounces categorised as inferred. The Promontorio deposit also hosts significant quantities of gold. Estimated measured and indicated gold resources contained within the mineralized diatreme system total 506,000 ounces with an additional 132,000 ounces inferred.

The La Negra Breccia prospect is situated approximately 6.5 km north of Kootenay's Promontorio silver resource and is contained within a 25 x 15 km mineralised corridor known as the Promontorio Mineral Belt. Initial exploration on La Negra included a successful trenching and surface sampling program that confirmed extensive silver mineralisation over a large 100 to 200 metres by 500 metres area on surface.

A follow up Phase I drill program on La Negra returned significant and consistent intervals of high-grade, widespread silver mineralisation extending from surface to depth, confirming a substantial new silver discovery.

Results from a Phase II drilling program on La Negra further confirmed the continuity of silver grades and the consistency of silver mineralisation to depth within the core of the diatreme breccia.

The program also further reinforced La Negra’s future potential as a low-cost, open pittable silver resource. Development of La Negra is currently under an option agreement with Pan American Silver

Pan American can earn a 75% interest Kootenay Silver’s Promontorio Mineral Belt silver properties, including the Promontorio and La Negra deposits, by paying US $8,050,000 over four years and spending US $8,000,000 on exploration. Pan American invested CDN $2,000,000 in Kootenay by subscribing for 9,090,909 Kootenay shares at CDN $0.22 per share.

Kootenay Silver began drilling its 100%-owned La Cigarra silver project in Chihuahua. The program is designed to test the RAM target and to expand La Cigarra’s resource by targeting continuity of high-grade trends recently identified within the resource.

Nymox share price under the cosh after press article

Nymox Pharmaceutical {NASDAQ: NYMX} shares have fallen sharply this week, losing one third of their value, after a Seeking Alpha article making some serious allegations against the company.

The company have not responded, but have announced progress in their drug development.

Comment

*The **Seeking Aplha** article linked below has made some serious allegations against Nymox, and a NY based lawyer is issuing a Class Action Lawsuit against Nymox, and the company has not responded.*

Under those circumstances it's hard to continue following the stock until the situation becomes clearer, and we will desist, but may issue updates on the legal case moving forward.

The Seeking Alpha article can be read HERE

Bronstein-Gewirtz–Grossman investgation article is HERE

Block Leviton LLP investigation announced HERE

Latest Nymox news release can be read HERE

Neometals announces significant drill results

Neometals Ltd {ASX: NMT}, Mineral Resources Limited {ASX: MIN}, and Ganfeng Lithium Co., {SZSE: 002460} provided an update on exploration drill results at the Mt Marion Lithium Project.

The update includes significant drilling results.

To read the full news release on PDF please click HERE

Kootenay Silver commence a core drill program at La Cigarra

Kootenay Silver Inc. {TSX.V: KTN} announced the commencement of a core drill program on its 100% owned La Cigarra silver project located in Chihuahua State, Mexico .

The drill program will total approximately 3,000 metres and is designed to test the high priority RAM target and expand the La Cigarra resource estimate.

Kootenay Silver Inc. {TSX.V: KTN} is pleased to announce the commencement of a core drill program on its 100% owned La Cigarra silver project located in Chihuahua State, Mexico .

The drill program will total approximately 3,000 metres and is designed to test the high priority RAM target and expand the La Cigarra resource estimate with a focus on determining continuity of high-grade trends recently identified within the resource.

Kootenay President and CEO James McDonald , stated, "*We are excited to start our drill program at La Cigarra, which will begin with the first ever drill test of the high-grade RAM silver target. The primary objectives of the program are to test this high priority target and to expand the existing La Cigarra resource which is open in three directions with particular attention to intercepting higher-grade silver. These are the first steps toward a new resource estimate and to proceeding with a Preliminary Economic Assessment on the project*."

Initial drilling will focus on the RAM Zone, where the first 8 holes are planned to target a potential high-grade silver area within a large structurally controlled anomalous silver trend measuring 3.8 kilometres in length. A program of re-logging aimed at gaining a deeper understanding of what controls the high grades is well advanced and will guide drilling along the extensions of the La Cigarra resource where several underlying high-grade silver zones have been identified. An example is at the southern boundary of the Las Carolinas Zone where hole 155 returned 23 metres of 138 g/t silver (See Northair News Release dated Dec 15, 2014) and remains open down dip and along strike to the southeast. Anomalous silver mineralization and alteration indicate an additional two kilometres of strike potential.

Results from the drill program will be announced as soon as the assays are received and interpreted by the Company. A larger drill program will be designed as progress and results of re-logging to assess the potential to model the high-grade zones and the 3,000 metre program are made and received.

Sampling and QA/QC

All technical information for the La Cigarra exploration program is obtained and reported under a formal quality assurance and quality control (“QA/QC”) program. Samples are taken under the direction of qualified geologists and stored in sealed bags. Samples are delivered by the Company via courier to ALS Minerals (“ALS”) in Chihuahua. The samples are dried, crushed and pulverized with the pulps being sent airfreight for analysis by ALS in Vancouver, B.C. Systematic assaying of standards is performed for precision and accuracy. Analysis for silver, zinc, lead and copper and related trace

elements was done by ICP four acid digestion, with gold analysis by 30 gram fire assay with an AA finish. All drilling will be with HQ core and has been contracted to BD Drilling from Guadalajara, Mexico . Further Quality Assurance and Control procedures and details on assays procedures and laboratories used are disclosed on the Kootenay Silver Inc. website.

Qualified Persons

The Kootenay technical information in this news release has been prepared in accordance with the Canadian regulatory requirements set out in National Instrument 43-101 (Standards of Disclosure for Mineral Projects) and reviewed on behalf Kootenay by James McDonald , P.Geo, President, CEO & Director for Kootenay, a Qualified Person.

About Kootenay Silver Inc.

Kootenay Silver Inc. is an exploration company actively engaged in the discovery and development of mineral projects in Mexico and in British Columbia, Canada . The Company’s top priorities are the advancement of the La Cigarra silver project and the Promontorio Mineral Belt, in Chihuahua, Mexico and Sonora, Mexico , respectively. The La Cigarra property is 26 kilometres from the historic mining city of Parral and boasts nearby power, good road access, gentle topography, and established infrastructure. La Cigarra currently hosts a resource estimate of 18.54 million tonnes containing 51.47 million ounces of silver in the Measured & Indicated categories grading 86.3 g/t silver and 4.45 million tonnes containing 11.46 million ounces of silver in the Inferred category grading 80 g/t silver. The mineralized system at La Cigarra has been traced over 6.5 kilometres and is defined at surface as a silver soil anomaly and by numerous historic mine

workings.

The La Cigarra silver deposit is open along strike and at depth and is approximately 25 kilometres north, and along strike, of Grupo Mexico’s Santa Barbara mine and Minera Frisco’s San Francisco del Oro mine. The Promontorio Mineral Belt includes the Company’s La Negra high-grade silver discovery and its Promontorio Silver Resource. The Promontorio Mineral Belt is under option to Pan American Silver whereby they can earn a 75% interest in the project with US$16 million of expenditures and payments with Kootenay retaining a 25% carried to production interest (see news release February 16 and March 4, 2016).

The Promontorio Silver Resource currently hosts a resource estimate of 44.5 million tonnes containing 92 million ounces of silver equivalent in the Measured & Indicated categories grading 64.3 g/t silver equivalent and 14.6 million tonnes containing 24.3 million ounces of silver equivalent in the Inferred category grading 52 g/t silver equivalent. The Company’s core objective is to create value by acquiring silver resources through discovery and acquisition and testing those resources with the ultimate goal of developing them into silver production if they are proven to be economically viable.

Scorpio Gold Announces Change

in Management

Scorpio Gold Corp. {TSX.V: SGN} announces the resignation of Peter J. Hawley from the position of President, effective immediately, for personal reasons.

Mr. Hawley has indicated that he will also retire from the position of CEO of the Company on October 31, 2016, or at such time as a replacement is found. He intends to remain as Chairman and a director of the Company.

Scorpio Gold Announces Change in Management

Vancouver, August 10, 2016 – **Scorpio Gold Corp. {TSX.V: SGN}** announced the resignation of Peter J. Hawley from the position of President, effective immediately, for personal reasons.

Mr. Hawley has indicated that he will also retire from the position of CEO of the Company on October 31, 2016, or at such time as a replacement is found. He intends to remain as Chairman and a director of the Company.

The Company also announces the promotion of Chris Zerga to the position of President effective immediately. Mr. Zerga has been with Scorpio Gold since its inception in 2009 and has been the General Manager for the Company’s Mineral Ridge and Goldwedge projects.

Mr. Zerga not only has familiarity with all aspects of the Company’s operations but brings over 29 years of mining

operations and management experience in Nevada with Freeport McMoran, Anglo Gold, Minorco, Newmont and Queenstake.

The Company's board of directors, management and staff would like to thank Mr. Hawley for his extraordinary efforts and tireless service in making Scorpio Gold a successful, low-cost gold producer. Mr. Hawley will continue to provide guidance as a director and Chairman of the Company.

Chris Zerga, President, comments, "*I would like to thank Peter and the board of directors for this opportunity and look forward to the associated challenges of the position. I have been the beneficiary of working closely with Peter since the Company's inception and will strive to make this a seamless transition*."

Peter J. Hawley comments, *"I look forward to working with Chris in his new leadership position. I credit him and his team's hard work over the difficult period of low metal prices, allowing me to step away and leave the Company in very capable hands, in a stable financial position and poised for growth*."

An independent search committee has been established to evaluate potential candidates for the position of CEO.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the Mineral Ridge gold

mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%). Mineral Ridge is currently in production as a conventional open pit mining and heap leach operation.

The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted immediately when needed.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
CEO

For further information please contact:
Chris Zerga, President
+1 819 825 7618
czerga@scorpiogold.com

Inovio Pharmaceuticals Reports 2016 Q2 Financial

Results

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} reported financial results for the quarter ended June 30, 2016.

The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to $5.3 million.
Inovio Pharmaceuticals Reports 2016 Second Quarter Financial Results

PLYMOUTH MEETING, Pa., Aug. 08, 2016 – **Inovio Pharmaceuticals, Inc. {NASDAQ: INO}** today reported financial results for the quarter ended June 30, 2016.

The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to $5.3 million. Total operating expenses were $24.4 million compared to $20.4 million. The net loss attributable to common stockholders was $18.7 million, or $0.26 per share, compared to $6.2 million, or $0.09 per share.

Revenue

The increase in revenue was primarily due to an increase in development payments from our DARPA Ebola grant.

Operating Expenses

Research and development expenses were $19.6 million compared to $16.7 million. The increase was primarily related to increased investment in our product development programs. General and administrative expenses were $5.8 million compared to $4.7 million.

Capital Resources

As of June 30, 2016, cash and cash equivalents and short-term investments were $134.5 million compared with $163.0 million as of December 31, 2015. There were 73.5 million shares outstanding and 81.2 million fully diluted.

The Company sold 119,400 shares of common stock at an average price of $11.12 per share, for net proceeds of $1.3 million, under the ATM common stock sales agreement implemented during the period.

Inovio's balance sheet and statement of operations are provided below. Form 10-Q providing the complete 2016 second quarter financial report can be found at: http://ir.inovio.com/secfilings.

Corporate Update

Clinical Development

The FDA and European Medicines Agency provided an affirmative path toward an indication for VGX-3100 to treat HPV-16/18-related high grade cervical dysplasia in a pivotal phase III registration study. We completed major commercial device design and manufacturing process development efforts, and are

in the final stage of testing. Completion of this extensive work will enable us to then submit our final package to the FDA in order to start the phase III in 4Q 2016.
Received approval from the FDA to initiate a phase I human trial to evaluate Inovio's Zika DNA vaccine (GLS-5700). This phase I, open-label, dose-ranging study with 40 healthy subjects is evaluating the safety, tolerability and immunogenicity of GLS-5700. Subsequent to the quarter Inovio announced the dosing of the first subject in this study. We expect to report interim immune response and safety data in 4Q 2016.
Inovio will continue to develop its hepatitis B DNA immunotherapy (INO-1800) independently following Roche's notice that it will discontinue its collaboration with Inovio and its development of INO-1800. INO-1800 was licensed to Roche from Inovio in 2013. All of Roche's rights to INO-1800, including the right to license the product to other parties, will be returned. Inovio will continue to advance its current phase I study of INO-1800, which is enrolling as planned in 30 clinical sites in the U.S. and Asia-Pacific regions. Inovio anticipates completing enrollment in the first half of 2017 and expects results in the second half of 2017.
The study has completed interim safety reviews with a favorable safety profile to date. Immunology analyses are planned after completion of enrollment.
Partnered with the National Cancer Institute and Mayo Clinic to initiate a phase I trial of our immunotherapy for hepatitis C (INO-8000). The dose escalation study will enroll patients in the early stages of chronic HCV infection to determine the therapy's ability to decrease and potentially eliminate HCV viral load, measure HCV specific immune responses and durability of these immune responses, and evaluate safety and tolerability.
Completed enrollment of 94 subjects in the phase I study of our PENNVAX®-GP HIV immunotherapy. After completing extensive immunogenicity analyses, we expect to report data in 1H 2017.
Completed enrollment of 22 subjects in the phase I study of

our HPV-driven cancer immunotherapy, INO-3112, in head & neck cancer patients. We expect to report additional immune response and safety data in 4Q 2016.
Completed enrollment of 62 subjects in the phase I study of our INO-5150 prostate cancer immunotherapy. We expect to report interim immune response and safety data in 4Q 2016.
Completed enrollment of 75 subjects in the phase I study of our GLS-5300 MERS vaccine. We expect to report interim immune response and safety data in 4Q 2016.
Corporate Development

Inovio completed the acquisition of all of Bioject Medical Technologies Inc.’s assets, including pioneering needle-free jet injection technology, devices, and intellectual property, for $5.5 million in cash and stock.
Inovio’s DNA-based monoclonal antibody technology will be deployed to develop new immunotherapy approaches to treat HIV. This work will be funded by a $23 million grant, called BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, from the National Institutes of Health to The Wistar Institute, an Inovio collaborator, and more than 30 of the nation’s leading HIV investigators.
Preclinical Development

Preclinical testing of our Zika virus synthetic vaccine induced robust and durable immune responses in mice and in non-human primates (monkeys).
About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute,

University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, please visit www.inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our

capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended June 30, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Minera IRL announce the resumption of drilling at Ollachea

Minera IRL Ltd. {BVL: MIRL} announced the resumption of drilling at the Ollachea flagship gold project in Puno, Southern Peru.

The program contemplates 5,230 mts of diamond drilling consisting of 23 holes drilled
from 6 platforms from within the Ollachea tunnel.

MINERA IRL ANNOUNCE RESUMPTION OF DRILLING AT THE OLLACHEA FLAGSHIP GOLD PROJECT

LIMA, PERU- August 8th, 2016) – **Minera IRL Ltd. {BVL: MIRL}** is pleased to announce the resumption of drilling at the Ollachea flagship gold project in Puno, Southern Peru.

The program contemplates 5,230 mts of diamond drilling consisting of 23 holes drilled
from 6 platforms from within the Ollachea tunnel. The target is the down-dip plunge of
the mineralisation to the east of the Minapampa ore body.

In 2013, three holes drilled off the tunnel intercepted mineralisation at grades generally superior to those encountered in main ore body.

DDH13-T01 20 mts grading 4.48 g/t Au
DDH13-T03 11 mts grading 5.47 g/t Au
DDH13-T04 9 mts grading 5.45 g/t Au
The drilling program is a condition precedent to access the second tranche of the US $240 million debt facility provided by Corporación Financiera de Desarrollo S.A. (“Cofide”) for the design, construction and commissioning of the mine. Other key milestones are completion of the optimisation studies for the mine extraction rate and metallurgical process and flow-sheet.

Both studies are focused on reducing the capital without prejudicing the targeted annual production of 100,000 oz. Au.
Mr. Francis O’Kelly, Chairman of Minera IRL commented, *“I am pleased to report*
recommencement of field activity at the mine site after a hiatus of almost one year due to circumstances that caused the temporary withdrawal of Community support for the
project. I am particularly gratified that the concerns of the Ollachea community have been successfully addressed and that the Company can now look forward to advancing the project in a cooperative spirit”
The drilling program has duration of 90 days. Assay results will be released periodically during the course of the project
FOR FURTHER INFORMATION, PLEASE CONTACT:
Minera IRL Limited
Carlos Ruiz de Castilla
Interim Chief Financial Officer +1 778 387 5434
Minera IRL S.A
Diego Benavides Norlander
President & CEO +51 1 418 – 1230

Cautionary Statement on Forward-Looking Information

Certain information in this news release, including information about the Company's financial or operating performance, information about the legislative regime to which the Company is subject, and other statements expressing management's expectations or estimates of future events, performance and exploration and development programs or plans constitute "forward-looking statements". Forward-looking statements often, but not always, are identified by words such as "seek", "believe", "expect", "do not expect", "will", "will not", "intend", "estimate", "anticipate", "plan", "schedule" and similar expressions of a conditional or future oriented nature identify forward-looking statements. Forward-looking statements are, necessarily, based upon a number of estimates and assumptions. While considered by management to be reasonable in the context in which they are made, forward- looking statements are inherently subject to political, legal, regulatory, business and economic risks and competitive uncertainties and contingencies. The Company cautions readers that forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Minera IRL's actual financial results, legislative environment, future performance and results of exploration and development programs and plans to be materially different than those expected or estimated future results, performance or achievements and that forward-looking statements are not guarantees of future performance, results or achievements.

Forward-looking statements are made as of the date of this news release and Minera IRL assumes no obligation, except as may be required by law, to update or revise them to reflect new events or circumstances. Risks, uncertainties and contingencies and other factors that might cause actual performance to differ from forward-looking statements include, but are not limited to, any failure to obtain or

complete project financing for the Ollachea Gold Project (including the Senior Debt Facility), changes in the price of precious metals and commodities, changes in the relative exchange
rates of the US dollar against the Peruvian nuevo sol, interest rates, legislative, political, social or economic developments both within the countries in which the Company operates and in general,contests over title to property, the speculative nature of mineral exploration and development, operating or technical difficulties in connection with the Company's development or exploration programs, increasing costs as a result of inflation or scarcity of human resources and input materials or equipment. Known and unknown risks inherent in the mining business include
potential uncertainties related to the title of mineral claims, the accuracy of mineral reserve and resource estimates, metallurgical recoveries, capital and operating costs and the future demand for minerals.

For additional information, please consult the Company's most recently filed MD&A and Annual Information Form.

Barkerville Gold Mines discovers high grade gold intersects at Cow Mountain

Barkerville Gold Mines Ltd. {TSXV: BGM} announced results from the ongoing Phase I exploration and category conversion drilling program on Cow Mountain at the Company's flagship Cariboo Gold Project.

Barkerville Gold Mines Intersects 11.82 g/t (0.34 oz/t) Au over 10.10 Metres including 68.80 g/t (2.01 oz/t) Au over 1.30 Metres in Cow Mountain Phase I Drilling – August 3rd, 2016

VANCOUVER, BC- August 3, 2016 – **Barkerville Gold Mines Ltd. {TSXV: BGM}** is pleased to announce results from the ongoing Phase I exploration and category conversion drilling program on Cow Mountain at the Company's flagship Cariboo Gold Project.

The results of these drill holes are presented in Table 1. A drill hole location plan map and longitudinal section are offered at the end of this release.

Drilling Highlights:

BGM-16-366: 16.97 g/t (0.49 oz/t) Au over 2.70 metres including 87.60 g/t (2.56 oz/t) Au over 0.50 metres
BGM-16-367: 8.70 g/t (0.25 oz/t) Au over 4.50 metres including 20.23 g/t (0.59 oz/t) Au over 1.90 metres including 8.64 g/t (0.25 oz/t) Au over 1.00 metres and 33.10 g/t (0.97 oz/t) Au over 0.90 metres
BGM-16-369: 20.31 g/t (0.59 oz/t) Au over 5.70 metres including 46.26 g/t (1.35 oz/t) Au over 2.40 metres including 121.50 g/t (3.54 oz/t) Au over 0.80 metres and 12.40 g/t (0.36 oz/t) Au over 1.00 metres
BGM-16-377: 31.94 g/t (0.93 oz/t) Au over 2.70 metres including 57.33 g/t (1.67 oz/t) Au over 1.50 metres including 21.40 g/t (0.62 oz/t) Au over 0.5 metres and 75.30 g/t (2.20 oz/t) Au over 1.00 metres
BGM-16-380: 11.82 g/t (0.34 oz/t) Au over 10.10 metres including 9.45 g/t (0.28 oz/t) Au over 1.00 metres and 68.80 g/t (2.01 oz/t) Au over 1.30 metres

BGM-16-385: 10.98 g/t (0.32 oz/t) Au over 5.50 metres including 33.53 g/t (0.98 oz/t) Au over 1.70 metres including 12.85 g/t (0.37 oz/t) Au over 0.85 metres and 54.20 g/t (1.58 oz/t) Au over 0.85 metres
BGM-16-400: 13.15 g/t (0.38 oz/t) Au over 4.25 metres including 43.20 g/t (1.26 oz/t) Au over 1.20 metres
*Note: Reported core lengths represent 50-75% true widths.

Phase I Drilling

The ongoing 30,000 metre Phase I drilling program at Cow Mountain is currently optimizing inferred gold mineralisation within a conceptual open pit. As per the updated 2015 Cow Mountain resource estimate performed by Snowden Mining Industry Consultants (Snowden), of Vancouver, British Columbia (refer to Company News Release dated March 31, 2015), drilling by previous operators from 1938-1981 was classified as inferred mineralisation because of lessened data confidence and was not simply a function of wider drill hole spacing. The BGM Phase I program is explicitly targeting these areas by replacing the historical gold intersections with modern drilling that conforms to CIM best practices and QAQC procedures. Based upon the Phase I drilling results to date, there has been excellent correlation between the historic mineralized intervals and the new 2016 Phase I drilling.

"*These latest drill results along with ongoing mapping, underground sampling, geologic modeling and historic data validation, continue to add positively to our confidence level of the Cow Mountain gold mineralisation*," commented **Chris Lodder, President and CEO of BGM**. "*After completion of this drilling program the rigs will be moved to begin drilling on Island Mountain and thus allow us to analyze the drill data*

and begin planning the next work program on Cow Mountain. We expect to have a resource statement for all exploration targets sometime in 2017."

Qualified Persons

Exploration activities at the Cariboo Gold Project are jointly administered on site by the Company's Project Managers, Maggie Layman, P.Geo. and Wanda Carter, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for the Company and has prepared, validated and approved the technical content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.

Quality Assurance – Quality Control

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the Company's secure facility in Wells, BC. Numbered security tags are applied to lab shipments for chain of custody requirements. The Company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, P.Geo. of Analytical Solutions Ltd., and is overseen by Paul Geddes, P.Geo, Vice President Exploration.

Drill core samples are submitted to ALS Geochemistry's analytical facility in North Vancouver, British Columbia for preparation and analysis. The ALS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample

is crushed and 250 grams is pulverized. Analysis for gold is by 50g fire assay fusion with atomic absorption (AAS) finish with a lower limit of 5ppb and upper limit of 10,000ppb. Samples with gold assays greater than 10,000ppb are re-analyzed using 50g fire assay with gravimetric finish, as well as 1,000g screen metallic fire assay. Samples are also analyzed using a 48 multi-elemental geochemical package by a 4-acid digestion, followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) and Inductively Coupled Plasma Mass Spectroscopy (ICP-MS).

For further information on Barkerville Gold Mines Ltd. please contact:

Chris Lodder
President & Chief Executive Officer
Suite 400-365 Bay Street
Toronto, Ontario, Canada
clodder@barkervillegold.com

About Barkerville Gold Mines Ltd

.
The Company is focused on developing its extensive land package located in the historical Cariboo Mining District of central British Columbia. Barkerville's mineral tenures cover 1,164 square kilometres along a strike length of 60 kilometres which includes several past producing hard rock mines of the historic Barkerville Gold Mining Camp near the town of Wells, British Columbia. The QR Project, located approximately 110 kilometres by highway and all weather road from Wells was acquired by Barkerville in 2010 and boasts a fully permitted 900 tonne/day gold milling and tailings facility. Test mining of the Bonanza Ledge open pit was completed in March of 2015 with 91,489 tonnes of ore milled producing 25,464 ounces of

gold. The Company has completed a number of drilling and exploration programs over the past 20 years and is currently compiling this data with all historical information in order develop geologic models which will assist new management and provide the framework to continue to explore the Cariboo Gold Project. An extensive drill program is currently underway with the goal of delineating additional high grade gold mineralisation.

Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As VP Regulatory Affairs

Inovio Pharmaceuticals, Inc. {NASDAQ: INO} announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs.

Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovio's regulatory strategies.

Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs

PLYMOUTH MEETING, PA – August 4, 2016 – **Inovio Pharmaceuticals, Inc. {NASDAQ: INO}** today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs.

Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovio's regulatory strategies, including leadership over regulatory submissions, regulatory compliance, advertising and promotion review, and registrations to support Inovio's product pipeline.

Dr. J. Joseph Kim, Inovio's President & CEO, said, "*Ami has shown technical excellence and leadership in successfully moving our DNA-based therapy for women's health, VGX-3100, through its phase II regulatory process. This is now leading to the initiation of phase III for this program before the end of this year. We expect her strategic guidance and counsel to be invaluable as we advance multiple cancer and infectious disease products through the clinical and regulatory process*."

Prior to Inovio, Dr. Brown was Director, Vaccine Operations, at the Sabin Vaccine Institute in Washington, D.C., where she contributed to the early work of the Sabin Vaccine Institute Product Development Partnership (Sabin PDP), an internationally recognized PDP for the creation of safe, effective, low-cost vaccines for tropical infections in developing countries. She had previous experience at the Johns Hopkins Bloomberg School of Public Health's Center for Immunization Research, the Emory University Department of Medicine, and the Centers for Disease Control and Prevention (CDC) at the National Center for HIV, STD and TB prevention. She began her career at the University of Pennsylvania Department of Pathology and Laboratory Medicine.

She holds a PhD from Johns Hopkins University's Bloomberg School of Public Health, a Master of Public Health (MPH) degree from Emory University's Rollins School of Public Health, and a BA in Biology from the University of

Pennsylvania.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.

For more information, visit www.inovio.com

CONTACT:
Bernie Hertel

+1 858 410 3101

bhertel@inovio.com

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events

or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the

company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended March 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Nymox Pharmaceutical director Robinson buys in the market again

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} Director James George Robinson purchased 22,500 shares of the company's stock in a transaction dated Friday, July 29th.

The stock was purchased at an average price of $3.86 per share, for a total transaction of $86,850.00.

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} Director James

George Robinson purchased 22,500 shares of the company’s stock in a transaction dated Friday, July 29th.

The stock was purchased at an average price of $3.86 per share, for a total transaction of $86,850.00.

Following the completion of the purchase, the director now owns 2,880,050 shares in the company, valued at $11,116,993.

Nymox Pharmaceutical Corp., formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.

Scorpio Gold to undertake a phase 2 exploration program in Nevada

Scorpio Gold Corp. {TSX.V: SGN} reports its intention to undertake Phase 2 of an exploration program on its Nevada Assets totalling approximately US$750,000.

This will include work at Mineral Ridge and Goldwedge.

VANCOUVER, BRITISH COLUMBIA– (Aug. 3, 2016) – **Scorpio Gold Corp. {TSX.V: SGN}** reports its intention to undertake Phase 2 of an exploration program on its Nevada Assets totalling approximately US$750,000.

Mineral Ridge Program

A breakthrough in the understanding of the Mineral Ridge deposit as it relates to gold emplacement resulting from a deep ductile strain event or events earlier this year, has led to the preparation by the Company of a detailed comprehensive phase 2 exploration Program, which will set the stage for growth in 2017. It is expected that the new phase 2 exploration program will consist of the following;

3.5 months of detailed field mapping by the Company's geology team which will focus on investigating the post mineral structural features in order to determine the localities that gold has originally formed in. This is expected to comprise of approximately 500 multi-element samples to aid in the understanding of the geology.

A 3 month cost effective in-house ground geophysical survey comprising of vertical gradient and total field magnets and VLF (Very Low Frequency) electromagnets over the areas of interest designed to delineate post mineral faulting as well as aid in the understanding of the geological architecture during the gold formation.

To be followed by 10 small diameter diamond drill holes in the first priority target derived from the above mentioned fieldwork and geophysical surveys which will set the stage for a more comprehensive 2017 drilling campaign.

10 HQ size diamond drill holes designed to test and further define the Drinkwater Highwall Open Pit economics.

5 HQ size diamond drill holes designed to test and further delineate the Bunkhouse Hill (Mary LC Phase 4) economics.

The estimated cost for this program is US$718,000.

Goldwedge Program

The Goldwedge exploration program is three-fold. First,

sampling the Goldwedge proposed Plan of Operations boundary, second sampling the Keystone – Jumbo area and third conducting an in-house cost effective vertical gradient and total field magnets and VLF (Very Low Frequency) electromagnets geophysical surveys.

In the Goldwedge area, soil sampling will be used to augment drillhole targeting in the vicinity of the Goldwedge mine and to understand the mineralisation controls in the collapsed caldera to the North of the Goldwedge mine.

In the Keystone – Jumbo area this program will be targeting structural intersections between East-West to East-Northeast structures and Northwest structures which have been identified as the main controls on mineralization in the Keystone and Jumbo pits in order to generate drill targets to include in future drill permit applications.

The geophysical surveys will help to understand geological and structural controls in the area, especially where ground cover is present.

The estimated cost for this program is US$33,000.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%).

Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages.

Scorpio Gold also holds a 100% interest in the advanced

exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted immediately when needed.

Scorpio Gold's President & CEO, Peter J. Hawley, PGeo., is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD, SCORPIO GOLD CORPORATION

Peter J. Hawley, President & CEO

The Company relies on litigation protection for forward-looking statements. This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "suggest", "indicate" and other similar words or statements that certain events or conditions "may" or "will" occur, and include, without restriction, any statements regarding the Company's proposed exploration programs for 2016, or future exploration programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks related to open pit mining and heap leach operations, including unanticipated changes in the mineral content of materials being mined; unanticipated changes in recovery rates; changes in project parameters; failure of equipment or

processes to operate as anticipated; the failure of contracted parties to perform; availability of skilled labour and the impact of labour disputes; delays in obtaining governmental approvals; the results of exploration and development programs and the timing and cost of such exploration and development programs; changes in metals prices; the availability of cash flows or financing to meet the Company's ongoing financial obligations; unanticipated changes in key management personnel; changes in general economic conditions; other risks of the mining industry; and those risk factors outlined in the Company's Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.

Scorpio Gold Corporation
Peter J. Hawley President & CEO
+1 819 825 7618
phawley@scorpiogold.com
www.scorpiogold.com

Inovio will Independently

Develop Hepatitis B Immunotherapy after Roche quits

Inovio Pharmaceuticals, {NASDAQ: INO} today announced the company will continue to develop its hepatitis B DNA immunotherapy (INO-1800) independently following Roche's notice that it will discontinue its collaboration with Inovio and its development of INO-1800.

Inovio will Independently Develop Hepatitis B Immunotherapy after Roche quits

PLYMOUTH MEETING, PA – August 3, 2016 – **Inovio Pharmaceuticals, {NASDAQ: INO}** today announced the company will continue to develop its hepatitis B DNA immunotherapy (INO-1800) independently following **Roche**'s notice that it will discontinue its collaboration with Inovio and its development of INO-1800.

INO-1800 was licensed to Roche from Inovio in 2013. All of Roche's rights to INO-1800, including the right to license the product to other parties, will be returned. Inovio will continue to advance its current phase I study of INO-1800, which is enrolling as planned in 30 clinical sites in the U.S. and Asia-Pacific regions. Inovio anticipates completing enrollment in the first half of 2017 and expects results in the second half of 2017.

This randomised, open-label, active-controlled, dose escalation study is evaluating the safety, tolerability, and immunogenicity of INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator in adults with chronic hepatitis B infection.

The primary endpoints are safety and tolerability. The secondary endpoints will evaluate the cellular and humoural immune response to INO-1800 and investigate the therapy's

effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care oral antiviral therapies. The study has completed interim safety reviews with a favorable safety profile to date. Immunology analyses are planned after completion of enrollment.

Dr. J. Joseph Kim, Inovio's President & CEO, said, "*While we acknowledge Roche's strategic decision in the area of hepatitis B, we are optimistic that our potent immunotherapy platform will make a difference in this globally important chronic viral infection, similar to what we have demonstrated in HPV-related disease. Inovio was already managing the phase 1 clinical trial so the study will continue on track without disruption.*"

About INO-1800 for Hepatitis B

Inovio has reported preclinical data showing its hepatitis B immunotherapy (INO-1800) generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. Notably, researchers found that hepatitis B-specific T cells exhibited a killing function and could migrate to and stay in the liver and cause clearance of chronically infected cells without evidence of liver injury. These results indicate that INO-1800 may have potential to treat chronic hepatitis B infection.

Hepatitis B and Liver Cancer

Chronic infection with hepatitis B virus is one of the major causes and risk factors for liver cirrhosis and liver cancer. The virus is very infectious, with over 240 million people chronically infected worldwide. More than 60 million of these people are at risk of the major complications of liver cirrhosis and liver cancer, which cause over 700,000 deaths globally each year.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight

against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline.

Partners and collaborators include MedImmune, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and Laval University.
For more information visit www.inovio.com

CONTACT:
Bernie Hertel
+1 858 410 3101
bhertel@inovio.com

* * *

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in

human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended March 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Cartier samples 21.3 g/t Au over five metres at Wilson

Cartier Resources Inc.{TSX.V: ECR} has provided its first results on the Wilson property, situated 15 kilometres east of Lebel-sur-Quevillon.

Channel sampling discovered several high grade values.

2016-08-02 06:50 PT – News Release

CARTIER SAMPLES 21.3 G/T AU OVER 5.0 M ON WILSON

Mr. Philippe Cloutier reports

Cartier Resources Inc.{TSX.V: ECR} has provided its first results on the Wilson property, situated 15 kilometres east of Lebel-sur-Quevillon. Channel sampling has confirmed high-grade values on the Toussaint deposit as shown by the results in the table.

Sample	Grade Au (g/t)	Length (m)(i)	Weighted average
35552	6.1	1.0	9.3 g/t Au sur 3.0 m
35553	19.3	1.0	

35554	2.6	1.0	
35559	1.0	1.0	5.7 g/t Au sur 4.0 m
35561	20.9	1.0	
35562	0.2	1.0	
35563	0.9	1.0	
35568	1.0	1.0	21.3 g/t Au sur 5.0 m
35569	90.6	1.0	
35571	4.1	1.0	
35572	6.7	1.0	
35573	4.4	1.0	
35579	9.5	1.0	5.8 g/t Au sur 3.0 m
35581	4.0	1.0	
35582	3.8	1.0	

(i) The length of the samples is expressed as the lengths of the channel. True
thickness is not yet estimated.

Northeast of the trench, sampling ends in high-grade gold values as the mineralized zone plunges abruptly under thick overburden.

“We are very satisfied with the results and they will help plan the next phases of fieldwork,” commented **Philippe Cloutier, President and CEO.**

Quality assurance/quality control

The scientific and/or technical information presented in this press release has been reviewed and approved by Gaetan Lavalliere, PGeo, PhD, and vice-president for Cartier. Mr.

Lavalliere is a qualified person as defined by National Instrument 43-101.

Neometals Diggers and Dealers Presentation

Neometals {ASX: NMT} are presenting at the annual Diggers and Dealers Conference in Kalgoorlie, Western Australia.

A copy of their presentation for this event is available to download.

To download the presentation PDF file, please click HERE

Gold in the summer doldrums

The price of gold and silver is currently in the summer doldrums, and perplexing investors that think it should be rising, yet this is a regular occurrence at this time of year.

Investors concerned by the recent lack of movement in the price of gold and silver

We have received calls from investors asking why, with all the world’s political problems and volatility, the price of gold and silver are trending sideways.

The answer is simply, if you study the historical charts for gold, this is normal for this time of year and called “the summer doldrums”.

The precious metals follow stocks and shares, who also generally tread water in the summer, only to push forward again once the holiday season finished in September.

June and July are normally the quiet months, although this year a 6% rise in the gold price in June was unprecedented, and perhaps reflects concern about events elsewhere, including of course, the Brexit vote.

Generally speaking. the best day to by a gold miner is August 1st, as this is normally the bottom of the cycle. Buying starts to creep back as August progresses in anticipation of the usual September surge.

Despite all the turmoil in the world, record low interest rates, negative bond yields, and military conflicts, it would seem that gold still followed the usual price pattern. August has arrived, so I would expect to see the producers and select well run explorers start another run soon, world events permitting of course.

Neometals Issue Quarterly Activities and Cashflow reports

Neometals {ASX: NMT} have issued their Quarterly Cashflow and Activities reports.

To access either or both of these reports, the links to click are pasted on the next page.

To access the Activities Report please click HERE

To access the Cashflow Report, please click HERE

Neometals post photos of construction progress at

Mt.Marion

Neometals {ASX: NMT} have posted photos of the progress they are making constructing their mine at Mt.Marion.

Every picture tells a story, and these look impressive.

To view the photos, please click HERE

Scorpio Gold Reports Results of AGM

Scorpio Gold Corp. {TSX.V: SGN} reported the re-election of Peter J. Hawley, Paul Parisotto, Brian Lock, Luc Pelchat, David W. Smalley, Andrew Lee Smith and Peter Brieger as Directors of the Company, at Scorpio Gold's AGM and special meeting of shareholders held July 25, 2016.

Scorpio Gold Reports Results of AGM

Vancouver, July 27, 2016 – **Scorpio Gold Corp. {TSX.V: SGN}** reports the re-election of Peter J. Hawley, Paul Parisotto, Brian Lock, Luc Pelchat, David W. Smalley, Andrew Lee Smith and Peter Brieger as Directors of the Company at Scorpio Gold's annual and special meeting of shareholders held July 25, 2016.

At the meeting, the Company's shareholders also approved the renewal of the Company's stock option plan and the re-appointment of Deloitte LLP as auditors of the Company, as set out in the Company's management information circular dated June 20, 2016.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%). Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted immediately when needed.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
President & CEO

Contact:
Peter J. Hawley, CEO
+1 819 825 7618
phawley@scorpiogold.com

Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial

Inovio Pharmaceuticals Incorporated {NASDAQ: INO} today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio's Zika DNA vaccine (GLS-5700).

This initial study features 40 healthy adult volounteers.

Inovio Pharmaceuticals Doses First Subject in Zika Vaccine Clinical Trial
Phase I trial approved by US FDA and Health Canada
PLYMOUTH MEETING, PA – July 26, 2016 – **Inovio Pharmaceuticals Incorporated {NASDAQ: INO}** today announced the dosing of the first subject in its multi-center phase I trial to evaluate Inovio's Zika DNA vaccine (GLS-5700).

In addition to the previously announced US FDA approval for the conduct of the study, Health Canada's Health Products and Food Branch has also approved this study, which will be conducted at clinical sites in Miami, Philadelphia, and Quebec City.

This phase I, open-label, dose-ranging study of 40 healthy adult volunteers is evaluating the safety, tolerability and immunogenicity of GLS-5700 administered with the CELLECTRA®-3P

device, Inovio's proprietary intradermal DNA delivery device. In preclinical testing, this synthetic vaccine induced robust antibody and T cell responses – the immune responses necessary to fight viral infections – in small and large animal models.

Dr. J. Joseph Kim, Inovio's President & CEO, said, "*The WHO declared Zika a public health emergency in February 2016 and every week new insights suggest that, similarly to dengue and Chikungunya, its medical and economic impact may be significant, pervasive and long-lasting. The U.S. Centers for Disease Control (CDC) estimates that there are 30 to 40 million U.S. travelers to Zika-affected areas annually. The resident population in the Americas at higher risk of Zika exposure has been estimated at nearly 300 million. It is easy to see the potentially harmful effect Zika could have and why a safe and effective vaccine, brought to market as quickly as possible, is critical for public health.*

"*Inovio's synthetic vaccine technology allows rapid development of new products to stimulate effective immune responses against targeted infectious diseases and cancers. Our Zika product has established a record as the fastest-ever vaccine development from conceptualization through human application, demonstrating the potential of our SynCon® platform to respond rapidly to global health emergencies. With enrollment now started, we expect to complete subject dosing and report interim phase I results later this year.*"

Inovio is developing its Zika vaccine, GLS-5700, with GeneOne Life Science, Inc. (KSE: 011000) and academic collaborators from the US and Canada who are also working to advance Inovio's Ebola and MERS vaccines into clinical development.

About Zika Virus

First identified in Uganda, Zika virus subsequently spread to equatorial Asia and over the past two years has rapidly spread through the South Pacific, Hawaii, South America, Central America, and the Caribbean.

Zika virus is a flavivirus, a family of viruses including yellow fever, dengue, and West Nile virus, which are introduced to people through mosquito bites. Because the Aedes species of mosquitoes that spreads Zika virus is found throughout the world there is concern that Zika will continue to spread to new countries and regions.

As of July 2016, 65 countries and territories reported continuing mosquito-borne transmission of the Zika virus, compared to 33 countries stated by WHO in their first Zika situation report in February 2016. Zika can also be sexually transmitted.

The most common symptoms of Zika virus are fever, rash, joint pain, and conjunctivitis. Zika has been linked to a severe birth defect called microcephaly which arises from infection during pregnancy. Microcephaly is marked by an abnormally small head and incomplete brain development.

Zika is also associated with Guillain-Barré syndrome, which causes muscle weakness of the limbs and in severe cases may cause almost total paralysis including the inability to breath. Recent reports suggest Zika may also be linked to other neurological abnormalities.

No vaccine or therapy currently exists for the prevention or treatment of infection with the Zika virus.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile.

With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, please visit www.inovio.com

CONTACT:
Bernie Hertel

+1 858-410-3101

bhertel@inovio.com

---

* * *

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its

collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended March 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.